During blood coagulation factor IXa binds to factor VIIIa on phospholipid membranes to form an enzymatic complex, the tenase complex. To test whether there is a protein-protein contact site between the Gla domain of factor IXa and factor VIIIa, we demonstrated that an antibody to the Gla domain of factor IXa inhibited factor VIIIa-dependent factor IXa activity, suggesting an interaction of the factor IXa Gla domain with factor VIIIa. To study this interaction, we synthesized three analogs of the factor IXa Gla domain (FIX 1-47 ) with Phe 9, Phe 25, or Val 46 replaced, respectively, with benzoylphenylalanine, a photoactivatable crosslinking reagent.
Introduction
Factor IX is composed of a single polypeptide comprising an N-terminal γ-carboxyglutamic acid (Gla) rich domain, an aromatic amino acid stack domain, two epidermal growth factor (EGF) domains and a C-terminal serine protease domain. The Gla domain contains 12 γ-carboxyglutamic acid residues, a posttranslationally modified glutamic acid residue. γ-Carboxylation occurs in the liver where the vitamin K-dependent carboxylase converts glutamic acid to γ-carboxyglutamic acid in an enzymatic reaction that requires vitamin K (1). In the presence of Ca ++ , the Gla domain folds to become a membrane-binding structure (2, 3) . In the absence of metal ions the Gla domain is largely unfolded and does not bind to membranes. Mg ++ ions, in the absence of Ca ++ , support folding of residues 12-47 of factor IX, but not folding of the membrane-interactive omega loop included in residues 1-11(4) whereas Ca ++ ions support folding of the membrane-binding omega loop and are necessary for function of factor IXa (5).
The metal ion-specific conformational changes have provided the basis for developing antibodies that recognize the Ca ++ -dependent 11 amino acid membrane binding region (6) .
Factor VIIIa is a cofactor for the factor IXa-mediated cleavage of factor X to factor Xa.
Factor VIII is synthesized as a single polypeptide chain composed of three A domains (A1, A2, A3), one B domain and two C domains (C1, C2) in the following sequence, A1-A2-B-A3-C1-C2 (7) . The A domains are homologous to ceruloplasmin, and the C domains are homologous to discoidin I, a phospholipid binding lectin (8) , and to a murine milk fat globule membrane protein (9) . The B domain has no known homology to any other protein. Factor VIII is variably cleaved, prior to its secretion, between the B and A3 domains to yield a heterodimeric protein composed of a variably sized heavy chain (A1-A2-B) and a light chain (A3-C1-C2). Thrombin activates factor VIII to factor VIIIa via several cleavages within both the heavy and light chains to yield a heterotrimeric protein (A1, A2, A3-C1-C2) that is non-covalently associated The C2 domain of factor VIII/VIIIa contains the major membrane binding motif (10, 11) . Properties of the membrane-binding interaction include high affinity (12) , high specificity for membrane binding sites that include phosphatidylserine (13) , and stereoselective interaction with phosphatidyl-Lserine (14) .
Factor IX is proteolytically activated to factor IXa, a serine protease. Factor VIII is activated to its cofactor form, factor VIIIa, via a proteolytic mechanism. Factor IXa and factor
VIIIa assemble on phosphatidyl-L-serine-containing phospholipid membranes in the presence of Ca ++ to form an enzymatic complex known as the tenase complex (2,3). The tenase complex converts factor X to factor Xa, the enzyme which converts prothrombin to thrombin leading to the conversion of fibrinogen to fibrin and the formation of a fibrin clot. Although much is known about the structures of both Factor IXa and Factor VIIIa from Xray crystallography and NMR spectroscopy (5, (15) (16) (17) , details about the interaction of Factor IXa with Factor VIIIa have been limited to the analysis of naturally occurring mutations in hemophilic patients or sitespecific mutagenesis studies (18) (19) (20) (21) . Analyses of factor IXa-factor VIIIa binding have revealed domain interactions between the serine protease domain of factor IXa and the A2 domain of factor VIIIa as well as the first epidermal growth factor domain of factor IXa and the A3 domain of factor VIIIa (22) . Furthermore, a naturally occuring mutation of the Gla domain of factor IX leads to loss of factor VIIIa-mediated tenase activity (23) . In this report, we use a synthetic analog of the factor IX Gla domain, FIX (Figure 1 ), which we modify by replacing specific hydrophobic amino acid with the photoactivatable amino acid, benzoylphenylalanine. With these Gla domain peptides, we provide direct evidence using a crosslinking strategy for the binding of the factor IX Gla domain to the light chain of factor VIIIa.
Experimental Procedures
Reagents: Factor IXa and factor X were purchased from Haematologic Technologies Inc.
Recombinant human factor VIII formulated in sucrose (Kogenate FS) was received as a gift from Bayer Canada and activated to factor VIIIa as described previously (24) . Bovine brain phosphatidylserine (PS), egg yolk phosphatidylcholine (PC), and dansylated phosphatidylethanolamine (dansyl-PE) were obtained from Avanti Polar Lipids. Chromogenic substrate S-2765 was purchased from Diapharma Group Inc. ESH8 antibodies were purchased from American Diagnostica. Antibodies to the Gla domain of factor IXa were prepared as previously described (6) . An antibody to γ-carboxyglutamic acid was a gift from Dr. Johan
Stenflo (25) . The fIX BPA analogues were synthesized as previously described (4). were determined by phosphorus analysis (27) .
Fluorescence Measurements: The fluorescence energy transfer experiments and fluorescence quenching experiments were performed as previously described (28) . Dissociation constants (K D ) were calculated as described previously (29) .
Crosslinking Experiments: Covalent cross-linking of BPA-labeled In addition, crosslinking experiments were carried out in the presence of increasing concentrations of factor IXa.
Immunoprecipitation: Immunoprecipitation experiments were carried out with ESH8, a monoclonal antibody to the C2 domain of factor VIIIa. After irradiation and photo-induced crosslinking, the samples were immunoprecipitated with ESH8, subjected to SDS-PAGE and analyzed by Western blotting as described for the crosslinking experiments.
Results
The tenase complex, assembled on phospholipid membranes, is composed of the enzyme, factor IXa, and the cofactor, factor VIIIa. To test the hypothesis that the factor IXa Gla domain might bind to factor VIIIa, inhibition of factor IXa-catalyzed activation of factor X were performed in the presence or absence of factor VIIIa using an antibody to the calcium-stabilized conformation of factor IXa [anti-FIX·Ca[II]-specific antibodies). The epitope recognized by this antibody is targeted against residues 1-11 within the Gla domain of factor IXa. Since antiFIX·Ca[II]-specific antibodies inhibit factor IX binding to phospholipid membranes (6), phospholipid membranes were omitted from this assay system. In the absence of phospholipid membranes, factor IXa can catalyze the conversion of factor X to factor Xa albeit at a significantly reduced rate. Anti-FIX·Ca[II]-specific antibodies inhibited the generation of factor Xa by factor IXa if factor VIIIa was present (Figure 2A ). In the absence of factor VIIIa, there was no inhibition of the conversion of factor X to factor Xa by factor IXa ( Figure 2B ). These results are consistent with antibody-mediated inhibition of the interaction of the Gla domain of factor IXa with factor VIIIa.
A peptide comprising the Gla and aromatic amino acid stack domains of factor IXa, FIX , was also used to study factor IXa Gla domain-factor VIIIa interactions. FIX has been previously demonstrated to be a good model for studying the biochemical properties of the factor IXa Gla domain (28) . To demonstrate direct binding between the Gla domain of factor IXa and factor VIIIa, analogs of FIX 1-47 containing benzoylphenylalanine (BPA) were synthesized. BPA forms covalent bonds with adjacent structures within a 3 Å radius when irradiated at 350 nm (30) . It has been previously used to identify the residues that constitute a phospholipid binding The ability of the BPA-containing FIX peptides to inhibit the conversion of factor X to factor Xa by factor IXa in the presence and absence of factor VIIIa was determined in the absence of phospholipid membranes. A representative experiment, depicted in Figure 4 , shows inhibition of factor IXa-catalyzed activation of factor X by FIX 1-47 25BPA in the presence ( Figure   4A ) but not absence of factor VIIIa ( Figure 4B ). These results suggest that FIX 1-47 25BPA can bind directly to a specific site in factor VIIIa, preventing factor VIIIa from binding to factor IXa and serving as a cofactor in the activation of factor X to factor Xa. The IC 50 of this inhibition is 3.8 ±0.35 µM. The IC 50 of the other peptides are generally similar as shown in Table 1 .Although somewhat higher activity was observed in the presence of very low concentrations of the FIX 25BPA peptide as shown in the representative experiment depicted in Figure 4A (~10% on average; four experiments), the basis for this effect is unclear. It could reflect some stabilization of the normally very labile factor VIIIa during the one hour assay period as it is not seen in the absence of factor VIIIa ( Figure 4B ). This observation notwithstanding, the overall effect of this peptide is to prevent tenase complex formation by inhibiting the binding of factor VIIIa to factor
IXa
To demonstrate direct binding between the factor IXa Gla domain and factor VIIIa and to identify the region on FIX 1-47 that is near or in the contact site that binds to factor VIIIa, crosslinking experiments were performed to determine which FIX Figure 6 , substantiates the conclusion that the region on factor VIIIa to which FIX 1-47 25BPA binds is the light chain (A3-C1-C2 domain).
To establish the specificity of the crosslinking of FIX 25BPA to the light chain of factor VIIIa, full length factor IXa was employed at different concentrations to inhibit crosslinking. As shown in Figure 7 , the addition of increasing amounts of factor IXa led to complete inhibition of the crosslinking of FIX 1-47 25BPA to factor VIIIa.
Discussion
In the present work, we demonstrate that the Gla domain of factor IXa interacts with the light chain of factor VIIIa. A schematic model of this complex, assembled on phospholipid membranes, is presented in Figure 8 . Because factor VIIa is homologous with factor IXa, the contact sites through which tissue factor activates factor VIIa provide useful comparisons to the contact sites through which factor VIIIa activates factor IXa. On-off rates using both fluorescence spectroscopy and surface plasmon resonance demonstrate three interactive sites between the enzyme, factor VIIa, and its co-factor, tissue factor. A site of interaction between the Gla domain of factor VIIa and tissue factor is one site of interaction analogous to that identified in the present work. This site is considered to be of lower affinity in comparison to the other sites of interaction. The similar properties that we describe for the factor VIIIa-factor IXa Gla domain complex is consistent with that report (35). Fluorescent labeling of the involved residues in tissue factor that contact factor VIIa confirm that these sites become protected from solvent upon binding factor VIIa (36).
Two independent lines of evidence suggest that the contact between the light chain of factor VIIIa and the factor IXa Gla domain is physiologically important. First, a naturally occurring mutation in the Gla domain of factor IXa leading to hemophilia B affect function only in the presence of factor VIIIa. This propisitus, with a substitution of glycine 12 by arginine, has a severe bleeding phenotype (23) . Second, factor IXa-factor VIIIa interactions can be inhibited by a peptide comprising the Gla domain of factor IXa, FIX .
Our data suggest an interaction between the C-terminal half of the Gla domain of factor IXa and the light chain of factor VIIIa. In the folded Gla domain Phe 25 is located at the distal In this study, we identify a region of the factor IXa Gla domain containing Phe 25 and
Val46 as a contact site with factor VIIIa. These contact sites are localized to the C-terminal portion of the Gla domain similar to two homologous serine proteases, factor VIIa and protein C.
The crystal structure of the factor VIIa-tissue factor complex demonstrates a direct interaction between the C-terminal region of the Gla domain of factor VIIa and tissue factor (37). In the case of the protein C-protein S complex, replacement of the Gla domain of protein C with that of prothrombin renders protein C activity independent of protein S, its co-factor. This protein S dependence localizes to residues 23-46 of the Gla domain of protein C (38).
In conclusion, our studies demonstrate a specific interaction between the Gla domain of factor IXa and the light chain of factor VIIIa. Given that both the Gla domain of factor IXa and the C2 domain of factor VIIIa are membrane binding structures, we envision these regions bound to membranes and to each other. Whether the occupancy of this contact site promotes allosteric activation of the factor VIIIa-factor IXa complex on phospholipid membranes remains to be determined. 
